Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of CardiologyWorking Group on Cardiovascular Pharmacotherapy and European Society of CardiologyWorking Group on Thrombosis [PDF]
, 2015 Agewall, Stefan +15 more
core +1 more source
Prevalence of Major Bleeding in Elderly Patients on Oral Anticoagulants for Non-Valvular Atrial Fibrillation: A Single-Center 12-Year Retrospective Review. [PDF]
Geriatrics (Basel)Kwan HF +4 more
europepmc +1 more source
Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK [PDF]
, 2018 E. Clay +5 more
openalex +1 more source
Tailoring Anticoagulant Therapy: Managing Interactions Between Carbamazepine and Direct Oral Anticoagulants (DOACs). [PDF]
CureusMohammed TH +4 more
europepmc +1 more source
Schlaganfallprävention bei Vorhofflimmern – Edoxaban als potenzielle neue Behandlungsmethode [PDF]
, 2011 openalex +1 more source
Selective Genicular Artery Embolisation for Recurrent Hemarthrosis Following Total Knee Arthroplasty: A Case Report. [PDF]
CureusGarlapati A +3 more
europepmc +1 more source
Peak and Trough Concentration Ranges of Factor Xa Inhibitors for Preventing Thromboembolic Stroke in Korean Patients with Non-valvular Atrial Fibrillation. [PDF]
Ann Lab MedPark JS +5 more
europepmc +1 more source
Abnormally high plasma concentrations of M-4, the active metabolite of edoxaban, at the onset of acute kidney injury in a patient receiving rifampin and clarithromycin: a case report [PDF]
Junichi Nakagawa +8 more
openalex +1 more source
The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults [PDF]
, 2015 Dolly A. Parasramupria +4 more
core +1 more source